Peutz-Jeghers Syndrome Research Fallback

Deep-research provider attempts were made after the ORPHA:2869 direct Orphanet/MONDO target was selected:

• timeout 120 just research-disorder falcon Peutz_Jeghers_Syndrome
• timeout 120 just research-disorder openai Peutz_Jeghers_Syndrome

Both commands printed the initial provider line, then stalled without producing a research output file and were terminated by the timeout. The curation therefore used the structured Orphanet cache plus already-fetched PubMed, GeneReviews, and ClinicalTrials.gov cache records as the auditable evidence base.

Literature Scope Checked

• references_cache/ORPHA_2869.md: direct Orphanet leaf record for Peutz-Jeghers syndrome, including definition, autosomal dominant inheritance, exact MONDO and OMIM mappings, STK11 gene assertion, prevalence, age of onset, and HPO phenotype rows.
• references_cache/PMID_19916169.md: clinical review supporting autosomal dominant inheritance and prevalence range.
• references_cache/PMID_20301443.md: GeneReviews record supporting childhood mucocutaneous pigmentation, GI polyp complications, malignancy spectrum, and endoscopic surveillance with polypectomy.
• references_cache/PMID_37054692.md: clinical guideline supporting germline STK11 pathogenic variants and autosomal dominant inheritance.
• references_cache/PMID_38660671.md: human PJS polyp evidence for impaired LKB1/AMPK signaling.
• references_cache/PMID_19541609.md: human PJS and LKB1 mouse-model evidence for mTORC1 hyperactivation and preclinical rapamycin response.
• references_cache/PMID_18311138.md: mesenchymal LKB1/TGF-beta mechanism, with both mouse-model and human-polyp evidence.
• references_cache/PMID_12650805.md: human PJS hamartoma evidence for COX-2 overexpression.
• references_cache/PMID_20051941.md: systematic review of high PJS cancer risk.
• references_cache/PMID_36970589.md: 566-case human cohort quantifying cumulative intussusception risk.
• references_cache/clinicaltrials_NCT06722534.md: trial rationale for investigational celecoxib chemoprevention.

Curation Conclusions

• Disease identity is the syndrome-level disorder ORPHA:2869, exact to MONDO:0008280 and OMIM:175200.
• The core disease mechanism is germline STK11/LKB1 tumor-suppressor loss with downstream AMPK impairment, mTORC1 activation, stromal TGF-beta signaling defects, COX-2/prostaglandin upregulation, and somatic second-hit-driven malignancy risk.
• Orphanet directly supports the syndrome phenotype profile, including oral mucosal pigmentation, multiple lentigines, GI hemorrhage, anemia, intestinal obstruction, abdominal pain, GI carcinoma, breast carcinoma, and pancreatic adenocarcinoma.
• Evidence-backed management includes endoscopic surveillance with polypectomy, genetic counseling/cascade testing, and investigational mechanism-directed pharmacotherapy with COX-2 or mTOR inhibition.